Serotonin inhibits apoptosis of pulmonary artery smooth muscle cell by pERK1/2 and PDK through 5-HT1B receptors and 5-HT transporters

Cardiovasc Pathol. 2013 Nov-Dec;22(6):451-7. doi: 10.1016/j.carpath.2013.03.003. Epub 2013 Apr 17.

Abstract

Background: Decreased apoptosis of pulmonary artery smooth muscle cells (PASMCs) plays a key role in pulmonary vascular remodeling in pulmonary hypertension (PH). However, the cause and mechanism of this decrease in apoptosis are still unclear. Serotonin (5-HT) has been shown to be involved in PH by inducing PASMC proliferation through the activation of 5-HT1B receptors (5-HT1BR) and 5-HT transporter (5-HTT). 5-HT1BR and 5-HTT are also involved in abnormal apoptosis in many other pathological processes. Therefore, we hypothesized that 5-HT induces decreases in PASMC apoptosis through 5-HT1BR and 5-HTT.

Methods: PASMCs were treated with 5-HT, and their proliferation and apoptosis were assayed. 5-HT1BR agonists, 5-HT1BR antagonist, 5-HTT antagonist, combined 5-HT1BR/5-HTT antagonists, extracellular signal-regulated kinase (ERK1/2) activation inhibitor peptide I (EPI) and pyruvate dehydrogenase kinase (PDK) inhibitor sodium dichloroacetate (DCA) were used to explore the mechanism by which 5-HT induce decrease in PASMC apoptosis.

Results: PASMCs stimulated by 5-HT showed an increase in proliferation and a decrease in apoptosis, accompanied by increase in pERK1/2, PDK, and mitochondrial transmembrane potential. The effects of 5-HT on the proliferation and apoptosis of PASMCs were similar to those of 5-HT1BR agonists and were markedly prevented by 5-HT1BR antagonist, 5-HTT antagonist, combined 5-HT1BR/5-HTT antagonists, EPI, or DCA.

Conclusions: 5-HT inhibits PASMC apoptosis through 5-HT1BR or 5-HTT. pERK1/2 and PDK are involved in the process of 5-HT inhibition PASMC apoptosis through 5-HT1BR or 5-HTT.

Keywords: Apoptosis; Pulmonary artery smooth muscle cell; Serotonin.

MeSH terms

  • Apoptosis / drug effects*
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Humans
  • Membrane Potential, Mitochondrial / drug effects
  • Mitogen-Activated Protein Kinase 1 / metabolism*
  • Mitogen-Activated Protein Kinase 3 / metabolism*
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / enzymology
  • Muscle, Smooth, Vascular / pathology
  • Myocytes, Smooth Muscle / drug effects*
  • Myocytes, Smooth Muscle / enzymology
  • Myocytes, Smooth Muscle / pathology
  • Phosphorylation
  • Protein Serine-Threonine Kinases / metabolism*
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / enzymology
  • Pulmonary Artery / pathology
  • Pyruvate Dehydrogenase Acetyl-Transferring Kinase
  • Receptor, Serotonin, 5-HT1B / drug effects*
  • Receptor, Serotonin, 5-HT1B / metabolism
  • Serotonin / pharmacology*
  • Serotonin 5-HT1 Receptor Agonists / pharmacology*
  • Serotonin 5-HT1 Receptor Antagonists / pharmacology
  • Serotonin Plasma Membrane Transport Proteins / drug effects*
  • Serotonin Plasma Membrane Transport Proteins / metabolism
  • Signal Transduction / drug effects

Substances

  • HTR1B protein, human
  • Pyruvate Dehydrogenase Acetyl-Transferring Kinase
  • Receptor, Serotonin, 5-HT1B
  • SLC6A4 protein, human
  • Serotonin 5-HT1 Receptor Agonists
  • Serotonin 5-HT1 Receptor Antagonists
  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin
  • Protein Serine-Threonine Kinases
  • MAPK1 protein, human
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3